This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
A researcher in a clinical trial or clinical study. (NCI) A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the principal investigator. (ICH E6) An individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team. (21CFR50.3) Investigator's Brochure
The hull of the mature bean is hard, water-resistant, and protects the cotyledon and hypocotyl (or "germ") from damage. If the seed coat is cracked, the seed will not germinate. The scar, visible on the seed coat, is called the hilum (colors include black, brown, buff, gray and yellow) and at one end of the hilum is the micropyle, or small opening in the seed coat which can allow the absorption of water for sprouting. Some seeds such as soybeans containing very high levels of protein can undergo desiccation, yet survive and revive after water absorption. A. Carl Leopold began studying this capability at the Boyce Thompson Institute for Plant Research at Cornell University in the mid-1980s. He found soybeans and corn to have a range of soluble carbohydrates protecting the seed's cell viability. Patents were awarded to him in the early 1990s on techniques for protecting biological membranes and proteins in the dry state.
Gaesser, Glenn A; Brooks, George A (1984). "Metabolic bases of excess post-exercise oxygen consumption: a review". Medicine & Science in Sports & Exercise. 16 (1): 29–43. doi:10.1249/00005768-198401000-00008. PMID 6369064.
According to the elders, roads to the districts had been closed for nearly two months because of cross-border fire by Pakistani forces, and Taliban authorities had neither reopened the routes nor built alternative roads as promised. Residents said that food supplies in local markets had been exhausted, and warned of a shortage of wheat and medicine in health centres. Later on the day, the roads leading to Kamdesh and Bargi Matal districts were temporarily reopened following a meeting between tribal elders of these districts and tribal elders of Pakistan's Chitral district. A polio vaccination team was attacked by militants in Hangu District with the subsequent clash resulting in the death of two militant whereas a policeman was killed and four more were injured. On 14 April, Punjab CTD claimed to have captured 16 "suspected terrorists" including a TTP suicide bomber. On 15 April, tribal elders from eastern Afghanistan and Pakistan's Chitral district reached an agreement to reopen key routes linking Kamdesh and Barg-i Matal in Nuristan after nearly two months of closure caused by firing from Pakistani border guards. The talks were held on the Pakistani side of the border, at a Pakistani military facility, and did not include Taliban representatives. Under the agreement, both sides committed to a ceasefire across areas including Nari, Kamdesh, Bargi Matal, Arandu, and Chitral. Local elders also said Pakistani forces asked communities not to allow Pakistani Taliban to shelter in the area, and that if anyone did so, local people should stand against them.
Sources: en.wikipedia.org
Further testing in a microfluidic blood vessel model lined with human endothelial cells showed that pNPs triggered a self-amplifying coagulation-like process, forming nanofibrous structures that occluded sections of the artificial vessel. These findings suggest that pNPs could serve as a synthetic alternative for enhancing clot formation and improving hemorrhage management in trauma care.
=== China === In July 2007, officials of the People's Republic of China seized US-produced pork for containing ractopamine residues. Further shipments of Canadian ractopamine-fed pork were seized in September 2007. In June 2019, customs inspectors in China detected ractopamine in a shipment of Canadian pork products destined for Chinese consumption. The Chinese government thereupon suspended not only pork, but also beef imports from Canada. Canadian Agriculture Minister Marie-Claude Bibeau stated that the CRFPCP certificate was a forgery and called in the RCMP, while Canadian Public Safety Minister Ralph Goodale stressed that the federal government would vigorously defend Canadian meat producers. It was also revealed that the Canadian Cattlemen's Association said in a statement that "We are fully confident in our meat production systems in Canada and the safeguards we have in place." Meanwhile, holes were found in the CRFPCP programme because the meat packer at the centre of the controversy was a chilled butcher shop only.<what> It was disclosed on 3 July that the Chinese authorities had discovered 188 falsified CRFPCP certificates.
Bone health refers to the overall condition and strength of the human skeletal system, which is crucial for maintaining mobility, preventing fractures, and supporting overall well-being throughout life. It is influenced by various factors, including genetics, nutrition, physical activity, and hormonal balance. Optimal bone health is characterized by adequate bone mineral density (BMD) and proper bone microarchitecture, which together contribute to bone strength. Osteoporosis, a skeletal disorder characterized by compromised bone strength and increased risk of fractures, is a major concern in bone health, particularly among older adults. Maintaining good bone health involves a combination of adequate calcium and vitamin D intake, regular weight-bearing exercise, and avoiding risk factors such as smoking and excessive alcohol consumption. Recent research has also highlighted the potential role of the gut microbiome in bone health, suggesting a complex interplay between various physiological systems in maintaining skeletal integrity. The human skeletal system is a dynamic structure that consistently works in balance with the rest of the body. In addition to supporting and giving structure to the body, a bone is the major reservoir for many minerals and compounds essential for maintaining a healthy pH balance. The deterioration of the body with age renders the elderly particularly susceptible to and affected by poor bone health.
Sources: en.wikipedia.org
Racial disparities have been a prominent and contentious aspect of the war on drugs in the US. In 1957, a belief at the time about drug use was summarized by journalist Max Lerner in his work, America as a Civilization: "As a case in point we may take the known fact of the prevalence of reefer and dope addiction in Negro areas. This is essentially explained in terms of poverty, slum living, and broken families, yet it would be easy to show the lack of drug addiction among other ethnic groups where the same conditions apply." The Anti-Drug Abuse Act of 1986 created a 100:1 sentencing disparity in the US for the trafficking or possession of crack when compared to penalties for trafficking of powder cocaine. The bill had been widely criticized as discriminatory against minorities, mostly blacks, who were more likely to use crack than powder cocaine. In 1994, studying the effects of the 100:1 sentencing ratio, the United States Sentencing Commission (USSC) found that nearly two-thirds of crack users were white or Hispanic, while nearly 85% of those convicted for possession were black, with similar numbers for trafficking. Powder cocaine offenders were more equally divided across race. The USSC noted that these disparities resulted in African Americans serving longer prison sentences than other ethnicities. In a 1995 report to Congress, the USSC recommended against the 100:1 sentencing ratio. In 2010, the 100:1 sentencing ratio was reduced to 18:1. Other studies indicated similarly dramatic racial differences in enforcement and sentencing.
== Spectroscopy, spectrometry, and crystallography == Physical organic chemistry often entails the identification of molecular structure, dynamics, and the concentration of reactants in the course of a reaction. The interaction of molecules with light can afford a wealth of data about such properties through nondestructive spectroscopic experiments, with light absorbed when the energy of a photon matches the difference in energy between two states in a molecule and emitted when an excited state in a molecule collapses to a lower energy state. Spectroscopic techniques are broadly classified by the type of excitation being probed, such as vibrational, rotational, electronic, nuclear magnetic resonance (NMR), and electron paramagnetic resonance spectroscopy. In addition to spectroscopic data, structure determination is often aided by complementary data collected from X-Ray diffraction and mass spectrometric experiments.
This looked like a declaration of war against the Catholic and monarchist majority in the Legislative Assembly, which had been elected on 28 May in a moment of panic. But the president again pretended to be playing the game of the Orléanists, as he had done in the case of the Constituent Assembly. The complementary elections of March and April 1850 resulted in an unexpected victory for the republicans which alarmed the conservative leaders, Thiers, Berryer and Montalembert. The president and the Assembly co-operated in the passage of the Loi Falloux of 15 March 1850, which again placed university instruction under the direction of the Church. A conservative electoral law was passed on 31 May. It required each voter to prove three years' residence at his current address by way of entries in the record of direct taxes. This effectively repealed universal suffrage: factory workers, who moved fairly often, were thus disenfranchised. The law of 16 July aggravated the severity of the press restrictions by re-establishing the "caution money" (cautionnement) deposited by proprietors and editors of papers with the government as a guarantee of good behaviour. Finally, an interpretation of the law on clubs and political societies suppressed about this time all the republican societies.
Russell Brand's live tour is postponed, as police investigate a further allegation of sexual assault by the celebrity, dating back to 2003. The UK government announces that Post Office workers who had wrongful convictions for false accounting and theft overturned will each be offered £600,000 in compensation. 19 September The UK government announces that commissioners will be appointed to oversee the running of Birmingham City Council following its recent financial troubles. The Scottish Government begins its legal challenge against Westminster over the UK government's decision to block the controversial Gender Recognition Reform (Scotland) Bill. 20 September Data released by the Office for National Statistics show that inflation fell from 6.8% in July to 6.7% in August, something that is attributed to a fall in food prices. Sunak announces a major rethink of the UK government's strategy to achieve net zero carbon output in the UK by 2050, including a delay in banning the sale of new petrol and diesel cars from 2030 to 2035. 21 September The Bank of England holds interest rates at 5.25% after inflation for August was lower than expected. Five Bulgarian nationals suspected of spying for Russia are to be charged with conspiracy to conduct espionage. Charles III addresses the French Senate during his state visit to France. News Corp chairman Rupert Murdoch announces his retirement and plan to hand over his businesses to his son Lachlan. Murdoch additionally owned the American broadcaster Fox and formerly Sky Group.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.